Loss of cortical GABA terminals in Unverricht-Lundborg disease

Neurobiology of Disease

Volumn 47, Issue 2, 2012, Pages 216-224

  Buzzi, Andrea ^a,b   Chikhladze, Maia ^c   Falcicchia, Chiara ^a,b   Paradiso, Beatrice ^a,b   Lanza, Giovanni ^a   Soukupova, Marie ^a,b   Marti, Matteo ^a,b   Morari, Michele ^a,b   Franceschetti, Silvana ^c   Simonato, Michele ^a,b  

^a UNIVERSITY OF FERRARA   (Italy)

^b National Institute of Neuroscience   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Cortex; Epilepsy; GABA; Myoclonus; Neurodegeneration

Indexed keywords

4 AMINOBUTYRIC ACID; CYSTATIN B; PROTEINASE INHIBITOR; VESICULAR INHIBITORY AMINO ACID TRANSPORTER;

4 AMINOBUTYRIC ACID RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; BRAIN CORTEX; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GABAERGIC SYSTEM; IMMUNOHISTOCHEMISTRY; INTERNEURON; KNOCKOUT MOUSE; MALE; MOUSE; MYOCLONUS EPILEPSY; NEOCORTEX; NERVE ENDING; NEUROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION; SYNAPTOSOME;

ADULT; ANIMALS; CEREBRAL CORTEX; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MICE; MICE, 129 STRAIN; MICE, KNOCKOUT; MIDDLE AGED; PRESYNAPTIC TERMINALS; UNVERRICHT-LUNDBORG SYNDROME;

EID: 84861677881     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.04.005     Document Type: Article

References (43)

1. Abrahamson M., et al. Cystatins. Biochem. Soc. Symp. 2003, 179-199.
2. Alger B.E., Nicoll R.A. Pharmacological evidence for two kinds of GABA receptor on rat hippocampal pyramidal cells studied in vitro. J. Physiol. (Lond) 1982, 328:125-141.
3. Badawy R.A.B., et al. Can changes in cortical excitability distinguish progressive from juvenile myoclonic epilepsy?. Epilepsia 2010, 51:2084-2088.
4. Bellocchio E.E., et al. Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter. Science 2000, 289:957-960.
5. Blazquez-Llorca L., et al. GABAergic complex basket formations in the human neocortex. J. Comp. Neurol. 2010, 518:4917-4937.
6. Canafoglia L., et al. Short and long interval cortical inhibition in patients with Unverricht-Lundborg and Lafora body disease. Epilepsy Res. 2010, 89:232-237.
7. Chaudhry F.A., et al. The vesicular GABA transporter, VGAT, localizes to synaptic vesicles in sets of glycinergic as well as GABAergic neurons. J. Neurosci. 1998, 18:9733-9750.
8. Cohen N.R., et al. New neuropathological findings in Unverricht-Lundborg disease: neuronal intranuclear and cytoplasmic inclusions. Acta Neuropathol. 2011, 121:421-427.
9. DeFelipe J., et al. Visualization of chandelier cell axons by parvalbumin immunoreactivity in monkey cerebral cortex. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:2093-2097.
10. Dijk J.M., Tijssen M.A.J. Management of patients with myoclonus: available therapies and the need for an evidence-based approach. Lancet Neurol. 2010, 9:1028-1036.
11. Franceschetti S., et al. A pathogenetic hypothesis of Unverricht-Lundborg disease onset and progression. Neurobiol. Dis. 2007, 25:675-685.
12. Hagemann G., et al. Effects of tetanus toxin on functional inhibition after injection in separate cortical areas in rat. Brain Res. 1999, 818:127-134.
13. Haltia M., et al. Neuropathological studies in three Scandinavian cases of progressive myoclonus epilepsy. Acta Neurol. Scand. 1969, 45:63-77.
14. Heines D.E. Neuroanatomy. An atlas of structures, sections and systems 2003, Lippincott Williams and Wilkins, Philadelphia, PA, USA.
15. Joensuu T., et al. Cystatin B: mutation detection, alternative splicing and expression in progressive myclonus epilepsy of Unverricht-Lundborg type (EPM1) patients. Eur. J. Hum. Genet. 2007, 15:185-193.
16. Kälviäinen R., et al. Clinical picture of EPM1-Unverricht-Lundborg disease. Epilepsia 2008, 49:549-556.
17. Koskenkorva P., et al. Motor cortex and thalamic atrophy in Unverricht-Lundborg disease: voxel-based morphometric study. Neurology 2009, 73:606-611.
18. Koskiniemi M., et al. Progressive myoclonus epilepsy: a clinical and histopathological study. Acta Neurol. Scand. 1974, 50:307-332.
19. Lehesjoki A.E., Koskiniemi M. Progressive myoclonus epilepsy of Unverricht-Lundborg type. Epilepsia 1999, 40(Suppl. 3):23-28.
20. Lehesjoki A.E., et al. Localization of a gene for progressive myoclonus epilepsy to chromosome 21q22. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:3696-3699.
21. Lehesjoki A.E., et al. Localization of the EPM1 gene for progressive myoclonus epilepsy on chromosome 21: linkage disequilibrium allows high resolution mapping. Hum. Mol. Genet. 1993, 2:1229-1234.
22. Lehtinen M.K., et al. Cystatin B deficiency sensitizes neurons to oxidative stress in progressive myoclonus epilepsy, EPM1. J. Neurosci. 2009, 29:5910-5915.
23. Manganotti P., et al. Hyperexcitable cortical responses in progressive myoclonic epilepsy: a TMS study. Neurology 2001, 57:1793-1799.
24. McIntire S.L., et al. Identification and characterization of the vesicular GABA transporter. Nature 1997, 389:870-876.
25. Minelli A., et al. Postnatal development of the vesicular GABA transporter in rat cerebral cortex. Neuroscience 2003, 117:337-346.
26. 3H]D-aspartate outflow from various in vitro preparations of the rat hippocampus. Neurochem. Int. 1997, 31:113-124.
27. Paradiso B., et al. Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:7191-7196.
28. Pennacchio L.A., et al. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 1996, 271:1731-1734.
29. Pennacchio L.A., et al. Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. Nat. Genet. 1998, 20:251-258.
30. Rinne R., et al. Reduced cystatin B activity correlates with enhanced cathepsin activity in progressive myoclonus epilepsy. Ann. Med. 2002, 34:380-385.
31. Rozas C., et al. Developmental inhibitory gate controls the relay of activity to the superficial layers of the visual cortex. J. Neurosci. 2001, 21:6791-6801.
32. Sbrenna S., et al. L-glutamate and gamma-aminobutyric acid efflux from rat cerebrocortical synaptosomes: modulation by kappa- and mu- but not delta- and opioid receptor like-1 receptors. J. Pharmacol. Exp. Ther. 1999, 291:1365-1371.
33. Shannon P., et al. Neuropathological changes in a mouse model of progressive myoclonus epilepsy: cystatin B deficiency and Unverricht-Lundborg disease. J. Neuropathol. Exp. Neurol. 2002, 61:1085-1091.
34. Shibasaki H. Neurophysiological classification of myoclonus. Neurophysiol. Clin. 2006, 36:267-269.
35. A receptors. Trends Pharmacol. Sci. 1997, 18:425-429.
36. Stone N.E., et al. Construction of a 750-kb bacterial clone contig and restriction map in the region of human chromosome 21 containing the progressive myoclonus epilepsy gene. Genome Res. 1996, 6:218-225.
37. Takamori S. VGLUTs: "exciting" times for glutamatergic research?. Neurosci. Res. 2006, 55:343-351.
38. Takamori S., et al. Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons. Nature 2000, 407:189-194.
39. Takamori S., et al. Immunoisolation of GABA-specific synaptic vesicles defines a functionally distinct subset of synaptic vesicles. J. Neurosci. 2000, 20:4904-4911.
40. Tongiorgi E., et al. Brain-derived neurotrophic factor mRNA and protein are targeted to discrete dendritic laminas by events that trigger epileptogenesis. J. Neurosci. 2004, 24:6842-6852.
41. Valzania F., et al. Facilitation of rhythmic events in progressive myoclonus epilepsy: a transcranial magnetic stimulation study. Clin. Neurophysiol. 1999, 110:152-157.
42. Virtaneva K., et al. Progressive myoclonus epilepsy EPM1 locus maps to a 175-kb interval in distal 21q. Am. J. Hum. Genet. 1996, 58:1247-1253.
43. Zucchini S., et al. FGF-2 overexpression increases excitability and seizure susceptibility but decreases seizure-induced cell loss. J. Neurosci. 2008, 28:13112-13124.